Author/Authors :
Masjedi، Mohammad-Reza نويسنده , , Fahimi، Fanak نويسنده , , Sharif-Kashani، Babak نويسنده , , Malek Mohammad، Majid نويسنده , , Saliminejad ، Leila نويسنده Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), , , Monjazebi ، Fateme نويسنده Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), ,
Abstract :
Background: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients (www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications.
Materials and Methods: The IPAH registry was opened in November 2009. Information of IPAH and PAH patients with a username and password were uploaded in the site. Data entry was possible only via the physicians and healthcare organizations via internet that were given a personalized username and password for entry. Following the patients’ profile submission, a scientific committee composed of a cardiologist and a pulmonologist who were selected by the Ministry of Health of Iran (MOH), evaluated the data. The eligibility of the patient to receive the medications was confirmed after evaluation. If the patient was eligible, 82% of the Bosentan cost was paid by MOH.
Results: To date, one hundred and sixteen patients (82 females, 34 males) have been registered. The mean pulmonary artery pressure by right heart catheterization was 69.24±17 mmHg (ranging from 35 to 110 mmHg).
Conclusion: The first online Iranian registry program for IPAH and PAH patients is believed to supply essential information for health care providers in the field.
